Evidence Trace, complete trial record

In plain terms

In plain terms: Metformin (for longevity) has been tested in human trials aimed at the relevant outcome and did not show benefit at the doses and durations studied. The animal research may be encouraging, but it has not yet translated to humans in these trials.

Metformin (for longevity)

D Not shown: no human trial shows benefit

Route 2 — tested in humans; benefit not shown

Category Longevity Rx

Class Biguanide · Prescription only

Evidence Randomized controlled trials

Reviewed August 2026

PMIDs 31557380 · 30548390 · 33071237

The endpoint this grade is based on: Objectively measured functional outcome, Tested in healthy older adults, twice, alongside the intervention EBL grades highest. Both trials found metformin reduced the benefit of exercise rather than adding to it.

The evidence as the record states it

Evidence record

PMID 31557380 PMID 30548390 PMID 33071237

Walton et al. (Aging Cell, 2019; PMID 31557380): randomized, double-blind, placebo-controlled multicenter trial, 94 healthy adults aged 65 and over without diabetes, metformin 1,700 mg/day or placebo through 14 weeks of progressive resistance training. The pre-specified hypothesis was that metformin would AUGMENT the muscle response to training. It did not; metformin blunted the training-induced hypertrophy. Konopka et al. (Aging Cell, 2019; PMID 30548390): randomized controlled trial in older adults, metformin inhibited the mitochondrial adaptations to aerobic exercise training. Kulkarni et al. (Aging (Albany NY), 2020; PMID 33071237) is the muscle transcriptome analysis of the Walton cohort and is cited for mechanism, not for the grade. TAME, the trial designed to test metformin against age-related disease, has not reported. The observational signal that people taking metformin outlive matched non-diabetic controls is not randomized and does not move a grade here. So the position is not that metformin is untested: it is that the two randomized trials that put it in the aging population both found it reduced the benefit of resistance and aerobic training, and resistance training is the intervention holding EBL's only exercise Grade A. Route 2: tested in humans on the actual molecule, result adverse.

PMID 31557380 PMID 30548390 PMID 33071237

Trials showing no benefit

Trial 1

PMID 31557380

Endpoint: Muscle hypertrophy in response to progressive resistance training (primary outcome)
Population: 94 healthy adults aged 65 and over without diabetes, metformin 1,700 mg/day or placebo, 14 weeks

Observation

Moderate. Randomized, double-blind, placebo-controlled, multicenter. The hypothesis was that metformin would AUGMENT the muscle response. It did the opposite: the authors report metformin blunted the hypertrophic response to training.

Trial 2

PMID 30548390

Endpoint: Mitochondrial adaptation to aerobic exercise training
Population: Older adults without diabetes, metformin or placebo during supervised aerobic training

Observation

Moderate. Randomized controlled trial. Metformin inhibited the mitochondrial adaptations exercise normally produces, consistent with the earlier finding that it antagonizes exercise-induced gains in insulin sensitivity and cardiorespiratory fitness.

Why Grade D Route 2 and not Grade C

Grade D Route 2 applies when a compound has been tested in humans and benefit was not shown. Metformin (for longevity) has been tested in 2 human trials on endpoints relevant to the claim being evaluated, and the primary endpoint was not met.

A randomized, placebo-controlled trial pre-specifying a meaningful clinical or functional endpoint and demonstrating statistically significant benefit would move this to Grade C or higher, depending on effect size, population size, and whether it is independently replicated.

What this grade covers and what it does not

Grade D on Route 2: tested, harm found. This is not a null result and it is not an absence of evidence. Two randomized trials put metformin into healthy older adults alongside supervised exercise, and both found it reduced the benefit of the training rather than adding to it. Walton pre-specified that metformin would augment the muscle response to 14 weeks of progressive resistance training and reported it blunted the hypertrophic response instead. Konopka reported metformin inhibited the mitochondrial adaptations aerobic training normally produces. Resistance training holds EBL's only exercise Grade A, and it is one of the two it interfered with. WHAT THIS GRADE DOES NOT COVER: this grades metformin taken for longevity by people who do not have diabetes. It says nothing about metformin prescribed for type 2 diabetes, where it is standard care, and nothing here is a basis for changing a prescribed medication. It also does not cover the question TAME was built to ask, whether metformin delays age-related disease, because TAME has not reported. The observational finding that metformin users outlive matched non-diabetic controls is not randomized and carries no letter here.

What would move this grade

A randomized, placebo-controlled trial pre-specifying a clinical aging endpoint and demonstrating statistically significant benefit on that primary endpoint would be sufficient to move this to Grade C or higher, depending on effect size and population.

How this was studied

Metformin 1,700 mg/day by mouth for 14 weeks alongside supervised progressive resistance training (Walton 2019; PMID 31557380), and metformin alongside 12 weeks of supervised aerobic training (Konopka 2019; PMID 30548390). Both trials enrolled adults aged 65 and over WITHOUT diabetes. The dose is the standard glycemic dose; no separate 'longevity dose' has been tested.

How to track whether this is working Prescription only; requires physician management. This record grades metformin as a longevity intervention in people who do not have diabetes. It says nothing about metformin prescribed for type 2 diabetes, where it is standard care.